Price movement over the last 24 hours
Alcon AG vs Royal Caribbean Cruises Ltd — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Royal Caribbean Cruises Ltd trades at $281.6 (market cap $75.70B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.3× Alcon AG's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| ALC | RCL | |
|---|---|---|
Market Cap | $32.69B | $75.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $365.84 |
52-Week Low | $62.02 | $246.71 |
Enterprise Value | $36.28B | $96.98B |
Dividend Yield | 0.54% | 1.77% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Royal Caribbean (RCL) trades at $282.26, down 4.74% on the day, showing bearish technical momentum but maintaining strong fundamentals. The company reported robust Q1 2026 earnings of $3.60 per share, beating expectations, with revenue growth accelerating from $16.5B in 2024 to $17.9B in 2025. Analyst consensus remains positive with a $325.10 price target, though technical indicators signal near-term caution with support at $283.
RCL presents a compelling investment case with strong profitability (50.41% ROE) and consistent earnings beats, though elevated debt levels and fuel cost sensitivity pose risks. The stock's current pullback near key support levels offers potential entry points for long-term investors seeking exposure to the recovering cruise industry with disciplined financial management.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →